CStone Pharmaceuticals logo

2616 - CStone Pharmaceuticals News Story

HK$9.5 0.2  1.8%

Last Trade - 9:08am

Sector
Healthcare
Size
Mid Cap
Market Cap £1.03bn
Enterprise Value £764.7m
Revenue £127.3m
Position in Universe 874th / 6154

BUZZ-China's CStone Pharma set for best day in over 7 weeks on new drug application

Thu 2nd September, 2021 8:07am
** Shares of immuno-oncology drugs developer CStone
Pharmaceuticals  2616.HK  jump 9.3% to HK$13.90, the biggest
daily percentage gain since July 12
    ** Stock on track to snap two consecutive sessions of
decline
    ** Shanghai-based company says National Medical Products
Administration of China has accepted its new drug application
(NDA) for sugemalimab as a consolidation therapy in patients
with unresectable stage III cell lung cancer, its eighth
NDA/supplemental NDA submitted by CStone (https://bit.ly/3gX1b1D)
    ** Says CStone has formed a strategic partnership with
Pfizer  PFE.N  that includes development and commercialization
of sugemalimab in mainland China and a framework to bring
additional oncology assets to the Greater China market
    ** Hong Kong's healthcare index  .HSCIH  falls 1.2%
    ** The Hang Seng China Enterprises Index  .HSCE  gains 0.7%
and the benchmark index  .HSI  is up 0.1%
    ** As of last close, the stock had surged 26.2% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.